



Oslo, September 15th – 17th, 2010

The oncology partnering event in Europe for biotechs,
pharma, investors and academia.



Oslo Cancer Cluster



Cancer-Bio-Santé

CLUSTER

www.eccp2010.com

The Oslo Cancer Cluster, Norway, and the Cancer – Bio – Santé Cluster, France, welcome the key players of the international oncology community to the second European Cancer Cluster Partnering Event:

ECCP2010 is a unique meeting place for Europe's most promising oncology biotechs, business development and licensing executives from the pharmaceutical industry and investors as well as for innovative researchers and clinicians.

ECCP2010 is a business meeting aiming to build partnerships between emerging and established players in oncology, attract investments to innovative biotech companies and foster collaborations.

ECCP2010 is dedicated to oncology companies focussing on diagnostics, therapeutics, drug delivery, imaging and medical devices.

ECCP 2010 will take place at Folketeateret in the centre of Oslo and will be opened with a welcome reception at The Norwegian Opera House on September 15th, 2010 at 7 pm.

ECCP2010 – Building partnerships to accelerate innovations in cancer treatment:

ONCOLOGY FOCUS

Meet biotech companies, pharma companies and venture capitalists during a compact and purely oncology-focused two-day event.

ONE-TO-ONE MEETINGS

Present and discuss partnering opportunities in one-to-one meetings.

Post your company profile and use the online partnering platform to pre-schedule meetings and to maximize your partnering success.

PROGRAMME WITH PARTNERING AS THE CENTRAL THEME


Benefit from lectures, case-studies and roundtables with leading industry experts.

Get an outlook to the decade ahead from "Oncology 2020" keynotes and learn about recent trends in R&D, business development and investments in six focused sessions.

NETWORKING

Expand your network by using excellent networking opportunities: two networking events in the evenings and breaks during the day offer multiple ways to connect.






PRELIMINARY PROGRAM as of April 22nd, 2010

September 15 th , 2010			
From 19:00	WELCOME RECEPTION "Den Norske Opera"	Mr Stian Berger Røslund, Governing Mayor of Oslo	
September 16 th , 2010			
8:15 – 9:15	Registration & Welcome Coffee		
9:15 – 9:30	WELCOME ADDRESS	Mr Pierre Montoriol, President Cancer-Bio-Santé Mr Jónas Einarsson, President Oslo Cancer Cluster	
9:30 – 11:00	ONCOLOGY 2020 Perspectives for the decade ahead Keynote presentations	Moderator: Jónas Einarsson, Chairman of the Board, Oslo Cancer Cluster <ul style="list-style-type: none"> Open innovation networks / personalized medicine (<i>title tba</i>) Prof. Jonathan Knowles, Inst. for Molecular Medicine Finland & Ecole Polytechnique Federale de Lausanne Perspectives for new drug development, Prof. Jean-Pierre Armand, General Director Inst. Claudius Regaud, Toulouse The global cancer burden – opportunities for the next decade, Doug Ulman, President of the Lance Armstrong Foundation Livestrong 	ONE-TO-ONE MEETINGS
11:00 – 11:20	Coffee Break		
11:20 – 12:30	PARTNERING Biomarkers – new companion diagnostics in oncology Pharma Needs Case Studies	Moderator: <ul style="list-style-type: none"> Abbott presentation (<i>invited</i>) Case Study: The Cancer Genome Project and the future of individualized molecular oncology Prof. Olli Kallioniemi, Inst. for Molecular Medicine Finland Case study (<i>invited</i>) 	ONE-TO-ONE MEETINGS
12:30 – 14:00	Networking Lunch		
14:00 – 15:15	CLINICAL TRIALS Oncology-focused networks accelerating R&D Presentations Roundtable	Moderator: Prof. Jean-Pierre Armand <ul style="list-style-type: none"> A European Clinical trial network to shorten development timelines, Prof. Jean-Pierre Armand, Institute Claudius Regaud, Toulouse A Nordic node and its contribution to the European clinical trial network, Prof. Steinar Aamdal, Oslo University Hospital OncoNET: a new model streamlining clinical development; Mr. Hans Boström, Director of Licensing & External Research, MSD PANEL: Prof. Gerd Mikus; NCT Heidelberg, additional participants <i>to be confirmed</i> 	ONE-TO-ONE MEETINGS
15:15 – 15:30	Coffee Break		
15:30 – 17:00	INVESTMENTS The anatomy of VC financing and big company partnering	Moderator: Carl Chr. Gilhuus-Moe, Senior Partner NeoMed Management <ul style="list-style-type: none"> Financing of Emerging Life Science Companies: A Venture Capitalist View, Erik Amble, Managing, Partner, NeoMed Management Big Company M&A and Strategic Alliances: Opportunities and Challenges, Stephen N. Oesterle, MD, SVP Medicine and Technology, Medtronic Inc. Strategy for early stage investments in the US and in Europe, Kermit Nash, Esqr., Gray Plant Mooty 	ONE-TO-ONE MEETINGS
17:00 – 17:20	PHARMA NEEDS	SPONSOR PRESENTATION	
From 19:00	NETWORKING EVENING		

September 17th, 2010

8:00 – 9:00	Registration & Welcome Coffee		
9:00 – 10:10	<p>ONCOLOGY 2020 Global Networks to speed-up innovation</p> <p>Keynote Presentation Roundtable</p>	<p>Moderator & Keynote Speaker: Prof. Neil L. Spector Director, Duke Translational Oncology Research; Co-Director Experimental Therapeutics Program</p> <ul style="list-style-type: none"> Translating scientific concepts into innovative treatments – lessons learned and outlook for the next decade; Prof. Neil L. Spector <p>ROUNDTABLE:</p> <ul style="list-style-type: none"> Rick Williams, CBO, The Hamner Institutes for Health Sciences Prof. Ren Jun; Executive Director, Clinical Trials Centre Peking University School of Oncology/Beijing Cancer Hospital and Faculty Researcher Duke CCC Mr. Lei Ting, General Director Beijing Pharma and Biotech Centre Jean-Pierre Saintouil, CEO Cancer-Bio-Santé Bjarte Reve, CEO Oslo Cancer Cluster 	ONE-TO-ONE MEETINGS
10:10 – 11:10	<p>PARTNERING Emerging strategies to tap innovation</p> <p>Pharma Needs Case Studies</p>	<p>Moderator:</p> <ul style="list-style-type: none"> Sanofi-Aventis presentation (<i>speaker to be announced</i>) Case Study: The Astra Zeneca and Cancer Research Technology Alliance, Dr Chris Sheldon, Astra Zeneca Case Study: Bristol-Myers Squibb – Biotech collaboration (<i>invited</i>) 	ONE-TO-ONE MEETINGS
11:10 – 11:30	Coffee Break		
11:30 – 12:30	<p>CLINICAL TRIALS How to be fast and cost-efficient</p> <p>Case studies</p>	<p>Moderator and Introduction: Henrik Lund, Global Vice President, Clinical Development, AstraZeneca</p> <ul style="list-style-type: none"> Case study: Micromet (<i>invited</i>) Case study: Hybrigenics (<i>invited</i>) 	ONE-TO-ONE
12:30 – 13:30	Networking Lunch		
13:30 – 15:10	<p>PARTNERING Positioning as key</p> <p>Pharma Needs Case Studies</p>	<p>Moderator:</p> <ul style="list-style-type: none"> Case study: Algeta-Bayer (<i>confirmed, details tbd</i>) Case study: Transgene – Novartis; Jean-Yves Bonnefoy, Vice President R&D Transgene Case study: Clavis Pharma and Clovis Oncology: The building up of a Trans Atlantic Alliance, Olav Hellebø, CEO, Clavis Pharma 	ONE-TO-ONE MEETINGS
15:10 – 15:30	CLOSING SESSION		
From 15:30	Closing Cocktail		





ECCP2010 – building on the success of ECCP2009

The first ECCP conference was held in Toulouse, France, in September 2009 and was a great success:

- 365 participants from 22 countries, representing 263 different companies met for two intense and interactive days.
- About 550 one-to-one meetings were arranged using the partnering platform and a similar number of meetings were spontaneously set-up on site.

Comments from last year's participants:

“A great partnering opportunity with a clear disease focus”

Per Walday, CEO, PCI Biotech

“High quality contacts in the partnering”

Susanne Werner, Project manager PR & Information, Oslo Teknopol

“Excellent networking opportunities”

Eric Pierce, Publisher, BioCentury

“It was great!”

Philippe Mondon, PhD, Chief Technical Officer (CTO), MilleGen

“Perfect organization!”

Bey Emmanuel, Senior scientist, ElexoPharm GmbH

“A very good initiative that should be carried on for several years”

Prof. Carl Borrebaeck, Director CREATE Health, Lund University



Registration

Register at www.eccp2010.com and benefit from multiple partnering options:

ECCP Pass (VAT excluded)*	Regular fee	Member fee**
Delegate	500 €	250 €
Additional Delegate	250 €	125 €
Investors	Please contact: js@radforsk.no	

**Applicable VAT will be added to the registration fee*

***Oslo Cancer Cluster and Cancer-Bio-Santé members*

Practical Information

For travel information and hotel booking, please see www.eccp2010.com

